Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5KX2H
|
|||
| Drug Name |
GSK3923868
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J40-J44, J47; ICD-9: 490-492, 494-496] | Phase 1 | [1] | |
| COPD [ICD-11: 1D6Y] | Phase 1 | [1] | ||
| Company |
GlaxoSmithKline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphatidylinositol-4-kinase beta (PI4KB) | Target Info | Inhibitor | [2] |
| Phosphatidylinositol-4-kinase beta (PI4KB) | Target Info | Inhibitor | [3] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05677347) A Randomized, Double-blind, Placebo Controlled, Single and Repeat Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Inhaled GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
| REF 3 | Clinical pipeline report, company report or official report of GlaxoSmithKline | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.